4
Changes in Ownership
Dianthus Therapeutics, Inc. /DE/ Filed Acc 0001992260-26-000009
EVP, Head of R&D sold 23,124 shares at an average $106.41 ($2,460,690)
- EVP, Head of R&D acquired 23,124 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Randhawa Simrat EVP, Head of R&D | 2026-09-01 | Option exercise 10b5-1 | +7,500 | $17.88 | $134,100 | 11,500 | D |
| Randhawa Simrat EVP, Head of R&D | 2026-09-01 | Option exercise 10b5-1 | +6,249 | $21.77 | $136,041 | 17,749 | D |
| Randhawa Simrat EVP, Head of R&D | 2026-09-01 | Option exercise 10b5-1 | +9,375 | $22.07 | $206,906 | 27,124 | D |
| Randhawa Simrat EVP, Head of R&D | 2026-09-01 | Sale 10b5-1 | −2,600 | $105.19 | $273,494 | 24,524 | D |
| Randhawa Simrat EVP, Head of R&D | 2026-09-01 | Sale 10b5-1 | −7,215 | $106.25 | $766,594 | 17,309 | D |
| Randhawa Simrat EVP, Head of R&D | 2026-09-01 | Sale 10b5-1 | −13,309 | $106.74 | $1,420,603 | 4,000 | D |
| Derivatives | |||||||
| Randhawa Simrat EVP, Head of R&D | 2026-09-01 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,500 | 56,776 | D | ||
| Randhawa Simrat EVP, Head of R&D | 2026-09-01 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,249 | 41,676 | D | ||
| Randhawa Simrat EVP, Head of R&D | 2026-09-01 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,375 | 87,500 | D | ||
| Open-market sales · 23,124 sh · avg $106.41 · $2,460,690 | |||||||
Loading xslF345X06/ownership.xml…